EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy

Nature Medicine

Volumn 17, Issue 5, 2011, Pages 589-595

  Lupberger, Joachim ^a,b   Zeisel, Mirjam B ^a,b   Xiao, Fei ^a,b   Thumann, Christine ^a,b   Fofana, Isabel ^a,b   Zona, Laetitia ^a,b   Davis, Christopher ^c   Mee, Christopher J ^c   Turek, Marine ^a,b   Gorke, Sebastian ^d   Royer, Cathy ^a,b   Fischer, Benoit ^b   Zahid, Muhammad N ^a,b   Lavillette, Dimitri ^e   Fresquet, Judith ^e   Cosset, François Loïc ^e   Rothenberg, S Michael ^f   Pietschmann, Thomas ^g   Patel, Arvind H ^h   Pessaux, Patrick ⁱ   Dofföl, Michel ⁱ   Raffelsberger, Wolfgang ^b   Poch, Olivier ^b   McKeating, Jane A ^c   Brino, Laurent ^b   Baumert, Thomas F ^a,b,i   more..

^a INSERM   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITÉ LYON 1   (France)

^f HARVARD MEDICAL SCHOOL   (United States)

^g INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^h MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; CLAUDIN 1; DASATINIB; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; LAPATINIB; PROTEIN TYROSINE KINASE INHIBITOR; VIRUS GLYCOPROTEIN; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VIVO STUDY; MEMBRANE FUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VIRUS ENTRY; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; ANTIGENS, CD; ANTIVIRAL AGENTS; BASE SEQUENCE; CELL LINE; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; LIGANDS; MEMBRANE PROTEINS; MICE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPHA2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRUS INTERNALIZATION;

HEPATITIS C VIRUS;

EID: 79955692689     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2341     Document Type: Article

References (53)

1. Tai, A.W. & Chung, R.T. Treatment failure in hepatitis C: mechanisms of non-response. J. Hepatol. 50, 412-420 (2009).
2. Hézode, C. et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360, 1839-1850 (2009).
3. Timpe, J.M. et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47, 17-24 (2008). (Pubitemid 351171037)
4. Zeisel, M.B., Cosset, F.L. & Baumert, T.F. Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology 48, 299-307 (2008). (Pubitemid 351975554)
5. von Hahn, T. & Rice, C.M. Hepatitis C virus entry. J. Biol. Chem. 283, 3689-3693 (2008).
6. Barth, H. et al. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J. Virol. 80, 10579-10590 (2006). (Pubitemid 44628904)
7. Pileri, P. et al. Binding of hepatitis C virus to CD81. Science 282, 938-941 (1998). (Pubitemid 28507525)
8. Scarselli, E. et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21, 5017-5025 (2002).
9. Evans, M.J. et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446, 801-805 (2007). (Pubitemid 46582027)
10. Ploss, A. et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457, 882-886 (2009).
11. Hidalgo, M. & Bloedow, D. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of erlotinib (Tarceva). Semin. Oncol. 30, 25-33 (2003). (Pubitemid 36828625)
12. Shepherd, F.A. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005). (Pubitemid 41058344)
13. Li, J. et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat. Chem. Biol. 6, 291-299 (2010).
14. Fafi-Kremer, S. et al. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J. Exp. Med. 207, 2019-2031 (2010).
15. Mee, C.J. et al. Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J. Virol. 83, 6211-6221 (2009).
16. Schlessinger, J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110, 669-672 (2002). (Pubitemid 35283957)
17. Thoresen, G.H. et al. Response to transforming growth factor (TGFα) and epidermal growth factor (EGF) in hepatocytes: lower EGF receptor affinity of (TGFα) is associated with more sustained activation of p42/p44 mitogen-activated protein kinase and greater efficacy in stimulation of DNA synthesis. J. Cell. Physiol. 175, 10-18 (1998). (Pubitemid 28101967)
18. Dreux, M. et al. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog. 5, e1000310 (2009).
19. Krieger, S.E. et al. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 51, 1144-1157 (2010).
20. Koutsoudakis, G. et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J. Virol. 80, 5308-5320 (2006).
21. Zeisel, M.B. et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 46, 1722-1731 (2007).
22. Dreux, M. et al. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J. Biol. Chem. 281, 18285-18295 (2006). (Pubitemid 44035485)
23. Harris, H.J. et al. Claudin association with CD81 defines hepatitis C virus entry. J. Biol. Chem. 285, 21092-21102 (2010).
24. Harris, H.J. et al. CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J. Virol. 82, 5007-5020 (2008). (Pubitemid 351657061)
25. Lavillette, D. et al. Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J. Virol. 81, 8752-8765 (2007). (Pubitemid 47242848)
26. Witteveldt, J. et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J. Gen. Virol. 90, 48-58 (2009).
27. Hiraga, N. et al. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. J. Hepatol. 51, 1046-1054 (2009).
28. Kamiya, N. et al. Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor. J. Gen. Virol. 91, 1668-1677 (2010).
29. Meuleman, P. et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 41, 847-856 (2005). (Pubitemid 40462948)
30. Higgins, B. et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 15, 503-512 (2004). (Pubitemid 38736950)
31. Schneider, M.R. & Wolf, E. The epidermal growth factor receptor ligands at a glance. J. Cell. Physiol. 218, 460-466 (2009).
32. Lackmann, M. & Boyd, A.W. Eph, a protein family coming of age: more confusion, insight, or complexity? Sci. Signal. 1, re2 (2008).
33. Singh, A.B. & Harris, R.C. Epidermal growth factor receptor activation differentially regulates claudin expression and enhances transepithelial resistance in Madin-Darby canine kidney cells. J. Biol. Chem. 279, 3543-3552 (2004). (Pubitemid 38140594)
34. Flores-Benitez, D. et al. Control of tight junctional sealing: roles of epidermal growth factor and prostaglandin E2. Am. J. Physiol. Cell Physiol. 297, C611-C620 (2009).
35. Blanchard, E. et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J. Virol. 80, 6964-6972 (2006). (Pubitemid 44025195)
36. Reiter, J.L. & Maihle, N.J. A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor. Nucleic Acids Res. 24, 4050-4056 (1996). (Pubitemid 26385340)
37. McCole, D.F., Keely, S.J., Coffey, R.J. & Barrett, K.E. Transactivation of the epidermal growth factor receptor in colonic epithelial cells by carbachol requires extracellular release of transforming growth factor-α. J. Biol. Chem. 277, 42603-42612 (2002). (Pubitemid 35285629)
38. Miao, H. et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16, 9-20 (2009).
39. Pestka, J.M. et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. USA 104, 6025-6030 (2007). (Pubitemid 47175652)
40. Rothenberg, S.M. et al. Modeling oncogene addiction using RNA interference. Proc. Natl. Acad. Sci. USA 105, 12480-12484 (2008).
41. Bartosch, B., Dubuisson, J. & Cosset, F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197, 633-642 (2003). (Pubitemid 36314658)
42. Pietschmann, T. et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. USA 103, 7408-7413 (2006). (Pubitemid 43727846)
43. Kato, T. et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125, 1808-1817 (2003). (Pubitemid 37500445)
44. Lavillette, D. et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41, 265-274 (2005). (Pubitemid 40173981)
45. Frecha, C. et al. Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus GP displaying lentiviral vectors. Blood 114, 3173-3180 (2009).
46. Sandrin, V. et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 100, 823-832 (2002). (Pubitemid 34832607)
47. Fofana, I. et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 139, 953-964, 964.e1-e4 (2010).
48. Meunier, J.C. et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J. Virol. 82, 966-973 (2008).
49. Lohmann, V. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110-113 (1999). (Pubitemid 29307577)
50. van den Heuvel, S. & Harlow, E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262, 2050-2054 (1993). (Pubitemid 24041887)
51. Wang, Y. et al. Negative regulation of EphA2 receptor by Cbl. Biochem. Biophys. Res. Commun. 296, 214-220 (2002). (Pubitemid 35002081)
52. Chahbouni, A., den Burger, J.C., Vos, R.M., Sinjewel, A. & Wilhelm, A.J. Simultaneous quantification of erlotinib, gefitinib and imatinib in human plasma by liquid chromatography tandem mass spectrometry. Ther. Drug Monit. 31, 683-687 (2009).
53. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63 (1983). (Pubitemid 14203433)